Freely Filtered 051: ADVOR turns the practice of sequential nephron blockade on its head by blocking the proximal tubule before the loop of Henle. Does it work? Join The Filtrate as we dissect the latest diuretic RCT.

The Filtrate looks at a trial that tries to dissect the bumps in creatinine we regularly see with Pip/Tazo. Is it AKI or pseudonephrotoxicity?

The Filtrate look at the latest contribution to Fluid Wars, this one looking at late resuscitation.

SODIUM-HF is the largest and longest RCT done looking at sodium restriction heart failure. The top line results show no effect but the more you look at the study the more problematic it is. The Filtrate take it to task.

TESTING is the latest IgA nephropathy trial and it is the comeback kid of nephrology trials. From a trial that was halted because of excess adverse events to a safe and effective therapy with just a few tweeks. Amazing turn around. Join the Filtrate as we put TESTING to the test with study author Sean Barbour.

The Filtrate: Joel Topf Nayan Arora Sophia Ambruso Swapnil Hiremath Josh Waitzman Special Guest: Natalie Bello Director of Hypertension Research at Cedars Sinai Editor: Nayan Arora Show Notes: NephJC summary of CHAP CHiPS TV show CHIPS study: Less-Tight versus Tight Control of Hypertension in Pregnancy Prevention, Diagnosis, and Management of Hypertensive Disorders of Pregnancy: a Comparison of International Guidelines (Pubmed) SFLT in preeclampsia from where else but NephMadness and...

The Guideline Draft is back! This time the 2022 ISPD Peritonitis Guidelines are on the clock! The Filtrate are joined by PD junky Jade Teakall and guideline author, Jeff Perl.

The SSaSS study is a landmark study in the study of sodium and its effect on blood pressure and mortality. Join the Filtrate as they do a deep dive.

The University of Alabama with Revicor have made a better pig. Better for transplanting. And they transplanted a pair of these into a brain dead patient. The filtrate discuss the case report with transplant surgeon, Josh Mezrich.

Freely Filtered is excited to be the final PodCast of the first NephMadness PodCrawl and we are covering the best region of NephMadness, Animal House!

Minimal change disease has classically been described as having negative immunofluorescence and to not be antibody mediated. But here comes Dr Weins with a fresh study smashing this orthodoxy. She proposes anti-nephrin antibodies as the etiologic agent driving minimal change disease.

The Filtrate: Joel Topf Swapnil Hiremath Matt Sparks Editor: Joel Topf Show Notes: The 2010 RFN Top Nephrology Stories The 2021 NephJC Top Nephrology Stories Number 10: AKIKI AKIKI 2 in The Lancet AKIKI 2 in NephJC AKIKI 2 on Freely Filtered Number 9: Effect of Salt Substitution on Cardiovascular Events and Death The Salt Substitute and Stroke Study (SSaSS) in the NEJM The Salt Substitute and Stroke Study (SSaSS) in NephJC FDA Issues Final Guidance Regarding Use of an Alternate Name for...

The Filtrate: Joel Topf Swapnil Hiremath Jennie Lin (who was only there because her plans got boxed by covid) Jordy Cohen Josh Waitzman Special Guest: Rajiv Agarwal (@AgarwalRajivMD) Editor: Joel Topf Show Notes: NephJC discussion of CLICK: http://www.nephjc.com/news/click4chlorthalidone CLICK Visual abstract: http://www.nephjc.com/news/2021/12/7/the-click-visual-abstract Hawthorne effect: https://en.wikipedia.org/wiki/Hawthorne_effect A nice discussion run in periods in clinical...

The Filtrate: Joel Topf Swapnil Hiremath Nayan Arora Jennie Lin Sophie Ambruso Editor Joel Topf Show Notes: Sign Up for NephSim Nephrons. Deadline 11/30. https://nephsim.com/nephsim-nephrons/ The Draft Board except for Swapnil’s picks because…Calvin Ball: https://docs.google.com/document/d/1Unk_27uqTpMGXrOyrxbI-2csKg2W_qnbbN7IE3wZY_Y/edit?usp=sharing Calvinball per the Calvin and Hobbes Wiki: Calvinball is a game invented by Calvin and Hobbes. Calvinball has no rules; the players make up...

Voclosporin is a new calcineurin inhibitors with reliable pharmacokinetics, i.e. no more therapeutic drug monitoring, and it was able to improve complete renal remission in lupus nephritis. But all that glitters is not gold. Join us as we dig deep into the landmark AURORA1 trial.

The KDIGO 2021 Hypertension Guidelines. We mixed things up and went with a Fantasy Football-style draft. Pick your favorite guideline, and remember not to take a kicker or a defense until the last rounds.

Nephrology has been the recent beneficiary of a handful of studies examining the impact of the timing of the initiation of dialysis in AKI. One of these trials, AKIKI, now has a genuine sequel. In 2016 AKIKI was the first multi-center RCT examining early initiation of dialysis versus late initiation of dialysis and showed that early initiation not only did not improve patient outcomes but resulted in a significant number of patients receiving dialysis that would have recovered kidney function...

Episode 035: The COVID-19 Pandemic changed everything and last fall the ASN set out to document how it affected our nephrology fellows. The ASN Workforce Committee adapted the Annual Fellow Survey to assess how the pandemic affected nephrology fellows in terms of burn out, education, and enthusiasm for the specialty.

Episode 034: A newly expanded filtrate assembled to discuss the tricky CONFIRM Trial recently published in the NEJM. We are assisted by Elliot Tapper, noted hematologist and member of #LiverTwitter.

On April 6, 2021 Fibrogen announced that the analysis of the cardiovascular outcomes was adjusted after the data was unblinded. When the data was reanalyzed without this adjustment roxadustat is less impactful. Importantly for this NephJC discussion, the previously impressive MACE and MACE+ advantage for incident dialysis is no longer found. Roxadustat remains non-inferior in all outcomes, though the confidence intervals have widened.

Roxadustat is the first HIF stabilizer up for FDA approval. There have been a number of roxa publications and today we took at the two most recent. One is a pooled analysis of incident dialysis patients: roxa versus epoetin alpha. And The second is a pre-dialysis CKD study of roxa versus placebo. Roxa represents well, but devils in the details. Join the filtrate as we go deep on roxa!

Roxadustat is the first HIF stabilizer up for FDA approval. There have been a number of roxa publications and today we took at the two most recent. One is a pooled analysis of incident dialysis patients: roxa versus epoetin alpha. And The second is a pre-dialysis CKD study of roxa versus placebo. Roxa represents well, but devils in the details. Join the filtrate as we go deep on roxa!

The DAPA program busted SGLT2i out of the diabetes paradigm by showing that dapagliflozen improved heart failure and CKD outcomes in a patients with or without diabetes.

The Filtrate welcome Dawn Caster and Alfred Kim to discuss lupus nephritis, B-cell biology and a new option for LN, belimumab.

The Filtrate welcome Anna Burgner and hypertension legend George Bakris to discuss the opera and RCT, Fidelio.